Australia markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.39+0.16 (+3.06%)
At close: 04:00PM EDT
5.40 +0.01 (+0.19%)
After hours: 05:50PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 545.78M
Enterprise value 218.89M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.59
Price/book (mrq)1.13
Enterprise value/revenue 2.27
Enterprise value/EBITDA -0.71

Trading information

Stock price history

Beta (5Y monthly) 1.52
52-week change 3-85.82%
S&P500 52-week change 3-13.21%
52-week high 343.12
52-week low 34.02
50-day moving average 35.88
200-day moving average 318.71

Share statistics

Avg vol (3-month) 34.12M
Avg vol (10-day) 34.05M
Shares outstanding 598.16M
Implied shares outstanding 6N/A
Float 883.66M
% held by insiders 11.52%
% held by institutions 1110.93%
Shares short (27 Feb 2023) 418.66M
Short ratio (27 Feb 2023) 47.37
Short % of float (27 Feb 2023) 425.33%
Short % of shares outstanding (27 Feb 2023) 419.01%
Shares short (prior month 30 Jan 2023) 416.28M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022


Profit margin -292.55%
Operating margin (ttm)-320.23%

Management effectiveness

Return on assets (ttm)-23.69%
Return on equity (ttm)-48.46%

Income statement

Revenue (ttm)96.3M
Revenue per share (ttm)1.00
Quarterly revenue growth (yoy)159.90%
Gross profit (ttm)-224.15M
EBITDA -294.63M
Net income avi to common (ttm)-281.72M
Diluted EPS (ttm)-2.73
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)436.23M
Total cash per share (mrq)4.44
Total debt (mrq)109.34M
Total debt/equity (mrq)22.59
Current ratio (mrq)4.40
Book value per share (mrq)4.97

Cash flow statement

Operating cash flow (ttm)-248.21M
Levered free cash flow (ttm)-148.77M